Controversies in chemotherapy of prostate cancer.
Heicappell
Rüdiger
R
Department of Urology, Universitätsklinikum Benjamin Franklin, Freie Universität, Berlin, Germany. heicappell@medizin.fu-berlin.de
D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy*; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000726:Androgen Antagonists / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000097:blood; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D002986:Clinical Trials as Topic; D000077143:Docetaxel; D004961:Estramustine / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008942:Mitoxantrone / Q000627:therapeutic use; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy; D017239:Paclitaxel / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010166:Palliative Care; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D013498:Suramin / Q000627:therapeutic use; D043823:Taxoids; D013739:Testosterone; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000726:Androgen Antagonists; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D014408:Biomarkers, Tumor; D043823:Taxoids; D000077143:Docetaxel; D004961:Estramustine; D013739:Testosterone; D013498:Suramin; D008942:Mitoxantrone; D017430:Prostate-Specific Antigen; D017239:Paclitaxel